Owkin
Tech bio company combining biological large language models, multimodal patient data, and agentic software. The Owkin K co pilot has two environments: K Navigator, an agentic research environment free to academic researchers that accelerates literature review across 26.5 million articles and 19 biomedical databases and explores spatial multiomic patient data, and K Pro, an enterprise co pilot that uses a single orchestrator to select and combine specialized biological AI skills across drug discovery and development. Both are powered by Owkin Zero, a fine tuned biological reasoning model. The company reports K Pro accelerating internal drug target identification from more than 12 months to roughly 3 months, validated through collaborations with AstraZeneca, Bristol Myers Squibb, and Sanofi, including a three year AstraZeneca licensing agreement to build biopharma agents. Owkin operates a group of entities spanning a biology foundation model (Bioptimus), diagnostics (Waiv), and a clinical stage drug program (Epkin); this record covers the software platform. Founded 2016 by Thomas Clozel, MD and Gilles Wainrib, PhD.
Capability Axes
The models are the product. Owkin Zero is a fine tuned biological reasoning model, and the K co pilot orchestrates specialized biological AI skills over multimodal patient data. Nothing in the offering functions without them.
Specific and architecturally described rather than gestured at: a named reasoning model (Owkin Zero), a stated orchestration approach in which a single intelligent orchestrator dynamically selects and combines specialized skills, and disclosed data foundations spanning 19 biomedical databases, 26.5 million articles, and spatial transcriptomics from the MOSAIC initiative. The related entity structure, including the Bioptimus foundation model, is also disclosed rather than obscured.
Commercial validation is strong and named: collaborations with AstraZeneca, Bristol Myers Squibb, and Sanofi, including a three year AstraZeneca licensing agreement specifically to build biopharma agents. Multi year licensing by a top tier pharma is meaningful third party validation of the platform. Held back from A because the headline performance claim, target identification compressed from more than 12 months to roughly 3, is vendor reported without published methodology or a stated comparison baseline.
Structure is disclosed even though amounts are not, and the two sided model is itself informative: K Navigator is free to academic researchers in beta with a waitlist and a stated six month evaluation period, while K Pro is enterprise licensed through demo, exemplified by a three year AstraZeneca agreement. A researcher can determine access terms without a sales call; a biopharma buyer cannot determine cost.
Clearly stated across two distinct audiences: academic researchers via K Navigator and biopharma decision makers via K Pro, spanning discovery through development. Held back from A because the company also spans a foundation model business, a diagnostics business, and a clinical stage drug program, and the boundaries between the software platform indexed here and those adjacent entities are not always drawn crisply in its own materials.
Pricing
Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.
| Entry Price | Pricing Basis | BAA Tier | Implementation | Source |
|---|---|---|---|---|
|
Free for academic researchers (K Navigator); contact the vendor for K Pro
|
Free academic tier; enterprise licensing for biopharma | — | — | Vendor Published |
Two tiers with different commercial models, both disclosed in structure though not in amount. K Navigator is free to academic researchers, currently in beta with a waitlist and a stated six month evaluation period. K Pro is an enterprise platform sold through demo and licensing, exemplified by a three year AstraZeneca agreement. No rate card published for the enterprise tier.